BioCryst Pharmaceuticals (NASDAQ:BCRX) Downgraded to “Neutral” at Bank of America

Bank of America lowered shares of BioCryst Pharmaceuticals (NASDAQ:BCRXGet Rating) from a buy rating to a neutral rating in a research note published on Monday, MarketBeat.com reports. They currently have $14.00 price target on the biotechnology company’s stock, down from their previous price target of $21.00.

Other equities research analysts have also recently issued research reports about the company. StockNews.com initiated coverage on BioCryst Pharmaceuticals in a report on Thursday, March 31st. They set a hold rating on the stock. Zacks Investment Research lowered BioCryst Pharmaceuticals from a hold rating to a sell rating in a research report on Tuesday, March 1st. Evercore ISI dropped their target price on BioCryst Pharmaceuticals from $25.00 to $15.00 in a research report on Friday, April 8th. Barclays boosted their price objective on BioCryst Pharmaceuticals from $17.00 to $22.00 in a report on Thursday, February 24th. Finally, HC Wainwright restated a buy rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a research note on Thursday, February 24th. Seven investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of Hold and an average target price of $19.91.

BCRX stock opened at $12.59 on Monday. The business’s fifty day moving average price is $16.49 and its 200 day moving average price is $14.63. BioCryst Pharmaceuticals has a 12-month low of $9.72 and a 12-month high of $19.99. The company has a market capitalization of $2.32 billion, a PE ratio of -12.22 and a beta of 2.34.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Rating) last announced its earnings results on Wednesday, February 23rd. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.09). The company had revenue of $47.16 million during the quarter, compared to analysts’ expectations of $48.18 million. Sell-side analysts expect that BioCryst Pharmaceuticals will post -1.38 EPS for the current fiscal year.

In related news, Director George B. Abercrombie sold 5,000 shares of the stock in a transaction on Tuesday, February 15th. The stock was sold at an average price of $18.50, for a total value of $92,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Helen M. Thackray sold 7,600 shares of BioCryst Pharmaceuticals stock in a transaction dated Friday, April 1st. The stock was sold at an average price of $16.20, for a total value of $123,120.00. The disclosure for this sale can be found here. 4.80% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in BCRX. J.W. Cole Advisors Inc. increased its position in BioCryst Pharmaceuticals by 2.0% during the fourth quarter. J.W. Cole Advisors Inc. now owns 36,800 shares of the biotechnology company’s stock valued at $510,000 after acquiring an additional 735 shares during the last quarter. Biondo Investment Advisors LLC boosted its stake in BioCryst Pharmaceuticals by 0.6% during the third quarter. Biondo Investment Advisors LLC now owns 267,480 shares of the biotechnology company’s stock valued at $3,844,000 after buying an additional 1,640 shares during the last quarter. Kalos Management Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 7.0% in the 4th quarter. Kalos Management Inc. now owns 25,359 shares of the biotechnology company’s stock valued at $340,000 after purchasing an additional 1,659 shares during the last quarter. DekaBank Deutsche Girozentrale lifted its stake in shares of BioCryst Pharmaceuticals by 2.8% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 67,065 shares of the biotechnology company’s stock valued at $894,000 after purchasing an additional 1,800 shares during the last quarter. Finally, GWM Advisors LLC raised its holdings in shares of BioCryst Pharmaceuticals by 16.0% in the third quarter. GWM Advisors LLC now owns 14,255 shares of the biotechnology company’s stock worth $205,000 after buying an additional 1,964 shares during the period. 57.08% of the stock is currently owned by institutional investors.

About BioCryst Pharmaceuticals (Get Rating)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Featured Stories

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.